An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Buxton Helmsley Issues Letter to Mallinckrodt Plc. Directors Regarding Bankruptcy Negotiations and Financial Disclosure Violations
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Negative)
Tags
Rhea-AI Summary
Buxton Helmsley Group accuses Mallinckrodt of accounting and securities fraud, highlights inaccurate representations of CFO
Positive
None.
Negative
Accusations of multibillion-dollar accounting and securities fraud scheme
Failure to make required write-downs of asset values
Violation of accounting standards and securities laws
Inaccurate representations of CFO
NEW YORK--(BUSINESS WIRE)--
The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company’s Board of Directors, regarding the Company’s continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360 and Regulation S-X, within its August 9, 2023, Form 10-Q filing with the U.S. Securities and Exchange Commission (the “Commission”).
On March 17, 2023, BHG had issued a public report to the Company’s Board of Directors (also delivered to the Commission and U.S. Senate Finance Committee), which extensively outlaid and alleged an evidenced multibillion-dollar accounting and securities fraud scheme historically and presently occurring at the Company; uniquely, “strong[ly] evidence[d]” by the Company’s own prior-professed standard of determining the fair value of assets securing capital structure interests. Within that March 17, 2023, public report issued by BHG, it was thoroughly laid out how the Company had not only arguably been committing these violations of accounting standards and securities laws long before the Company’s Chapter 11 bankruptcy filing on October 12, 2020, but opted to apparently merely resume the scheme of concealing asset value depreciation expenses from the Company’s Commission-filed financial statements upon its emergence from reorganization proceedings, in violation of GAAP ASC 350/360 and Regulation S-X.
Since BHG’s March 17, 2023, public report, the Company has neither denied nor rebutted the “strong[ly] evidence[d]” (the Company’s own prior-professed evidentiary standard) apparent multibillion-dollar accounting and securities fraud scheme laid out therein.
Within the Letter today, BHG also highlighted how the Company has now corrected the inaccurate representations related to the licensing/credentials of Chief Financial Officer Bryan Reasons, but only after BHG was forced to publicly notify the Pennsylvania State Board of Accountancy within BHG’s April 28, 2023, follow-up letter to the Company (due to the Company’s apparent refusal to voluntarily correct the inaccurate representation after BHG’s initial March 17, 2023, public letter/report).
The Letter issued by BHG to the Company today, in addition to BHG’s March 17 and April 28, 2023, public correspondence, may be found at: https://www.buxtonhelmsley.com/mnk/
About Buxton Helmsley: The Buxton Helmsley Group, Inc. is a premier financial service, asset management and securities research firm, providing an array of services to a diversified group of individuals, corporations, trusts, and other entities. The firm’s headquarters are in New York City.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit